Clinical Trials Browser

Phase EARLY_PHASE1 × Myasthenia Gravis × 90 days × Clear all

NCT07392528 2026-02-11

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Phase EARLY_PHASE1 Not yet recruiting

15 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica

NCT07337785 2026-01-22

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Phase EARLY_PHASE1 Recruiting

36 enrolled

Multiple Sclerosis, Myasthenia Gravis, Recurrence, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating